HCM
SRNE

Highbridge Capital Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Highbridge Capital Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-10,900
Closed -$91K – 1903
2015
Q3 		$91K Buy
+10,900
New +$174K ﹤0.01% 1441

Other funds holding SRNE

WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Highbridge Capital Management's SRNE Position: Q4 2015 in Review

Highbridge Capital Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2015, closing a stake of 10,474 shares — an estimated $88K sold.

Highbridge Capital Management first reported a position in SRNE in Q3 2015 and held it in 1 quarter. The position peaked at $88K in Q3 2015. 84 funds tracked by Wall St. Rank hold SRNE as of Q4 2015.

  • Highbridge Capital Management reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Highbridge Capital Management sold 10,474 Sorrento Therapeutics, Inc. shares in Q4 2015, an estimated $88K.
  • Highbridge Capital Management first reported a position in Sorrento Therapeutics, Inc. in Q3 2015 and held it in 1 quarter.
  • Highbridge Capital Management's Sorrento Therapeutics, Inc. position peaked at $88K in Q3 2015.
  • 84 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2015.

Based on Highbridge Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.